Reimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancer

BMC Urology

Volumn 15, Issue 1, 2015, Pages

  Shahinian, Vahakn B ^a   Kuo, Yong Fang ^b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Androgen deprivation; Prostate cancer; Reimbursement

Indexed keywords

GONADORELIN AGONIST; ANTIANDROGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CERTIFICATION; DRUG INDICATION; FEMALE; HUMAN; INAPPROPRIATE PRESCRIBING; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; MEDICAL PRACTICE; MEDICAL SOCIETY; MEDICARE; MIDDLE AGED; PHYSICIAN INCOME; PRIVATE PRACTICE; PROSTATE CANCER; REIMBURSEMENT; UROLOGIST; CLINICAL PRACTICE; ECONOMICS; PREVALENCE; PROSTATIC NEOPLASMS; STATISTICS AND NUMERICAL DATA; TRENDS; UNITED STATES; UNIVERSITY HOSPITAL; UROLOGY;

ACADEMIC MEDICAL CENTERS; AGED; ANDROGEN ANTAGONISTS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MALE; MEDICARE; PRACTICE PATTERNS, PHYSICIANS'; PREVALENCE; PROSTATIC NEOPLASMS; UNITED STATES; UROLOGY;

EID: 84927948461     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/s12894-015-0020-y     Document Type: Article

References (24)

1. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321(7):419-24.
2. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002;168(1):9-12.
3. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103(8):1615-24.
4. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103-6.
5. Painter MR. Reimbursement issues with hormonal therapies for prostate cancer. Rev Urol. 2005;7 Suppl 5:S44-7.
6. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer. J Clin Oncol. 2007;25(34):5359-65.
7. Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med. 2010;363(19):1822-32.
8. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154-64.
9. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23(31):7897-903.
10. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448-56.
11. Warren J, Klabunde C, Schrag D, Bach PB, Riley GF. Overview of the SEER-medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(suppl IV):3-18.
12. Baldwin L-M, Adamache E, Klabunde CN, Kenward K, Dahlman C, Warren J, et al. Linking physician characteristics and medicare claims data: issues in data availability, quality and measurement. Med Care. 2002;40(suppl IV):82-95.
13. Chodak GW, Keane T, Klotz L. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology. 2002;60(2):201-8.
14. Welch HG, Albertsen PC, Nease RF, Bubolz TA, Wasson JH. Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med. 1996;124(6):577-84.
15. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst. 2006;98(12):839-45.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
17. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258-67.
18. Chang SL, Liao JC, Shinghal R. Decreasing use of luteinizing hormone-releasing hormone agonists in the United States is independent of reimbursement changes: a medicare and veterans health administration claims analysis. J Urol. 2009;182(1):255-60. discussion 261.
19. Krahn M, Bremner KE, Tomlinson G, Luo J, Ritvo P, Naglie G, et al. Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use? BJU Int. 2011;108(10):1588-96.
20. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol. 1997;79(6):933-41.
21. McDermed J, Strum S, Scholz M. The androgen deprivation syndrome (ADS): the incidence and severity in prostate cancer (PC) patients (PTS) receiving hormone blockade (HB). Proc Am Soc Clin Oncol. 1998;17:315a.
22. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol. 1999;161(4):1219-22.
23. Herr HW, O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol. 2000;163(6):1743-6.
24. Voss JD, Schectman JM. Prostate cancer screening practices and beliefs. J Gen Intern Med. 2001;16(12):831-7.